Vorinostat: all 244 studies that test it
Page 2 of 3. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.
- Trial for Locally Advanced Breast Cancer Using Vorinostat Plus ChemotherapyCompletedNCT00574587Phase 1/2Results posted
- Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk LymphomaCompletedNCT00561418Phase 1Results posted
- Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)TerminatedNCT00555399Phase 1/2Results posted
- Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.TerminatedNCT00503971Phase 1/2Results posted
- Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)TerminatedNCT00486720Phase 2Results posted
- Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT00481078Phase 2Results posted
- Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)CompletedNCT00479232Phase 1Results posted
- A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)TerminatedNCT00473889Phase 2/3Results posted
- A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)TerminatedNCT00424775Phase 1Results posted
- Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)CompletedNCT00423449Phase 1Results posted
- A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)CompletedNCT00373490Phase 1Results posted
- Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast CancerCompletedNCT00368875Phase 1/2Results posted
- Phase II Trial of SAHA & Tamoxifen for Patients With Breast CancerCompletedNCT00365599Phase 2Results posted
- Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the UrotheliumTerminatedNCT00363883Phase 2Results posted
- Vorinostat in Treating Patients With Progressive Metastatic Prostate CancerCompletedNCT00330161Phase 2Results posted
- Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedNCT00324870Phase 1/2Results posted
- Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney CancerTerminatedNCT00324740Phase 1/2Results posted
- Vorinostat in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00305773Phase 2Results posted
- Vorinostat in Treating Patients With Kidney CancerCompletedNCT00278395Phase 2Results posted
- Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast CancerCompletedNCT00262834Phase 2Results posted
- Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast CancerCompletedNCT00258349Phase 1/2Results posted
- Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's LymphomaCompletedNCT00253630Phase 2Results posted
- A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)TerminatedNCT00251589Phase 1/2Results posted
- Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeCompletedNCT00238303Phase 2Results posted
- Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00138203Phase 2Results posted
- Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerCompletedNCT00134043Phase 2Results posted
- Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's LymphomaCompletedNCT00132028Phase 2Results posted
- Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast CancerTerminatedNCT00132002Phase 2Results posted
- Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)CompletedNCT00128102Phase 3Results posted
- A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)CompletedNCT00127127Phase 1Results posted
- An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)TerminatedNCT00127101Phase 1Results posted
- Vorinostat in Treating Patients With Metastatic or Unresectable MelanomaCompletedNCT00121225Phase 2Results posted
- Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))CompletedNCT00111813Phase 1Results posted
- Suberoylanilide Hydroxamic Acid in Advanced Solid TumorsCompletedNCT00106626Phase 1Results posted
- Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV ViremiaWithdrawnNCT05700630Phase 1
- Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCCWithdrawnNCT05608369Phase 2
- Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different LocationsCompletedNCT04357873Phase 2
- Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s DiseaseWithdrawnNCT04339751Phase 2
- Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
- Voronistat in Pediatric Patients With Drug Resistant EpilepsyStatus unknownNCT03894826Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell TransplantationActive, not recruitingNCT03843528Phase 1
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow TransplantationActive, not recruitingNCT03842696Phase 1/2
- Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerActive, not recruitingNCT03742245Phase 1
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
- Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer DiseaseTerminatedNCT03056495Phase 1
- Vorinostat in Patients With Class 2 High Risk Uveal MelanomaWithdrawnNCT03022565Early Phase 1
- HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced MelanomaCompletedNCT02836548Phase 1/2
- Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 InfectionTerminatedNCT02707900Phase 1
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionCompletedNCT02475915Phase 1/2
- Epigenetic Reprogramming in Relapse AMLTerminatedNCT02412475Phase 1
- Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic CancerCompletedNCT02349867Phase 1
- Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung CancerStatus unknownNCT02151721Phase 1
- Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnNCT02114502Phase 2
- Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)CompletedNCT02108002Phase 1
- Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantCompletedNCT02083250Phase 1
- MLN9708 and Vorinostat in Patients With Advanced p53 Mutant MalignanciesCompletedNCT02042989Phase 1
- Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast CancerWithdrawnNCT01695057Not applicable
- Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDSCompletedNCT01617226Phase 2
- Study of Curcumin, Vorinostat, and SorafenibWithdrawnNCT01608139Phase 1
- Vorinostat and Concurrent Whole Brain Radiotherapy for Brain MetastasisTerminatedNCT01600742Phase 2
- Vorinostat in Treating Patients With Metastatic Melanoma of the EyeActive, not recruitingNCT01587352Phase 2
- Vorinostat Plus FND in Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT01578343Phase 2
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
- Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance TherapyWithdrawnNCT01501370Phase 2
- A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)TerminatedNCT01500538Phase 2
- Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaWithdrawnNCT01492881Phase 2
- Vorinostat in ChildrenCompletedNCT01422499Phase 1/2
- Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid MalignanciesCompletedNCT01421173Phase 1
- Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)CompletedNCT01394354Phase 1/2
- Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell LymphomaWithdrawnNCT01386398Phase 3
- High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent GliomaTerminatedNCT01378481Phase 1
- Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral TherapyStatus unknownNCT01365065Phase 2
- A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural MesotheliomaWithdrawnNCT01353482Phase 1/2
- Study of Pazopanib and Vorinostat in Patients With Advanced MalignanciesCompletedNCT01339871Phase 1
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT01297764Phase 1/2
- Study of Carfilzomib and Vorinostat for Relapsed or Refractory LymphomaCompletedNCT01276717Phase 1
- Sirolimus or Vorinostat and Hydroxychloroquine in Advanced CancerCompletedNCT01266057Phase 1
- Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent NeuroblastomaCompletedNCT01208454Phase 1
- Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate CancerTerminatedNCT01174199Phase 1
- A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and LymphomasCompletedNCT01132911Phase 1
- Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01130506Phase 1
- Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
- Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast CancerCompletedNCT01084057Phase 1
- Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
- Sorafenib and Vorinostat in Treating Patients With Advanced Liver CancerCompletedNCT01075113Phase 1
- Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell CarcinomaCompletedNCT01064921Phase 1
- Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01059552Phase 1
- A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01038388Phase 1
- Hydroxychloroquine + Vorinostat in Advanced Solid TumorsCompletedNCT01023737Phase 1
- N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed NeuroblastomaCompletedNCT01019850Phase 1
- Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
- Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic CancerCompletedNCT00983268Phase 1
- Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)TerminatedNCT00972842Phase 1/2
- Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung CancerCompletedNCT00946673Phase 1
- Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)CompletedNCT00918489Phase 2
- Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous SystemCompletedNCT00867178Phase 1
- A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential ThrombocythaemiaStatus unknownNCT00866762Phase 2
- Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma PatientsTerminatedNCT00857324Phase 1/2
- Relapsed and/or Refractory Non-Hodgkin Lymphoma StudyWithdrawnNCT00837174Phase 2